Tarsus Pharmaceuticals (TARS) Could Be 38% Undervalued Following Cautious Earnings Expectations

Investors are watching Tarsus Pharmaceuticals (TARS) ahead of its upcoming quarterly report, with expectations for a loss alongside higher revenue compared with last year and a cautious Zacks Rank of #4.

See our latest analysis for Tarsus Pharmaceuticals.

At a share price of US$58.52, Tarsus Pharmaceuticals has seen its share price decline 27.6% year to date, even though the 1 year total shareholder return is 46.3%. This suggests long term holders are still sitting on strong gains despite more recent share price weakness ahead of the earnings update.

If you are considering how this kind of setup might appear in other parts of the market, it can be useful to scan for stocks with different growth stories using the 41 healthcare AI stocks

The recent slide in Tarsus Pharmaceuticals after strong 1 year gains leaves a straightforward puzzle. Are you looking at a stock where the big move is already done, or is there still meaningful upside that current pricing does not reflect?

Most Popular Narrative: 37.8% Undervalued

Against the last close of $58.52, the most followed narrative for Tarsus Pharmaceuticals points to a higher fair value, anchored in long term revenue and margin ambitions that go well beyond the upcoming quarter.

Accelerated patient and physician adoption of XDEMVY, driven by a robust direct-to-consumer campaign and increased unaided awareness, points to ongoing demand expansion among an estimated 25 million potential U.S. patients, suggesting material runway for future top-line revenue growth.

Read the complete narrative.

Curious what sits behind that confidence? The narrative leans on rapid revenue expansion, a sharp shift in profitability and a future earnings multiple that undercuts the wider pharmaceuticals group.

Based on this narrative, Tarsus Pharmaceuticals is assigned a fair value of $94.11, using a 7.11% discount rate and detailed assumptions for revenue growth, margins and future valuation multiples. This compares with the current share price of $58.52 and implies that, if those long term projections play out as expected, the stock would be trading below the level suggested by the modelled cash flows and earnings power.

The same narrative framework also assumes a larger future revenue base and a materially higher profit margin than today, which together help to justify the higher valuation level that analysts have set out. A key question for any investor is whether those inputs align with personal expectations on product adoption, competition and the investment needed to build out the rest of the pipeline.

Result: Fair Value of $94.11 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, Tarsus Pharmaceuticals still carries clear risks, including heavy dependence on XDEMVY, as well as the high ongoing commercial and R&D spend required to support its broader pipeline story.

Find out about the key risks to this Tarsus Pharmaceuticals narrative.

Next Steps

With Tarsus Pharmaceuticals showing both appealing growth narratives and clear risk factors, it makes sense to review the underlying data for yourself and move promptly. To see a concise summary of the main upsides alongside the key concerns that investors are focused on, start with the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Tarsus Pharmaceuticals?

If Tarsus Pharmaceuticals is on your radar, do not stop there. Broaden your watchlist with other focused ideas that could sharpen your overall investment approach.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com